**LETTER TO JMG**

**Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes**

A B Csoka, H Cao, P J Sammak, D Constantinescu, G P Schatten, R A Hegele

**Key points**
- Hutchinson-Gilford Progeria Syndrome (HGPS), a “premature aging” disease, is caused by dominant mutations in LMNA encoding lamin A/C. Typical probands are heterozygous for a point mutation (G608G) in LMNA, which leads, by altered splicing, to an abnormally truncated version of lamin A, which we term the “progerin” isoform.
- Thirteen cell lines of atypical progeroid patients were obtained from Coriell Cell Repositories (Camden, NJ, USA), selected based on the search terms “atypical progeria” or “progeroid” phenotype. By genomic PCR followed by direct sequencing, we identified three novel heterozygous LMNA mutations in three probands: one patient with atypical HGPS (R644C), another with severe Werner’s syndrome (E578V), and a third with Seip syndrome (T10I).
- The R644C mutation was previously reported in dilated cardiomyopathy and may represent pleiotropy causing different phenotypes.
- Fibroblasts from these three probands had abnormal nuclear membrane architectures characterised by the blebbing or rupture seen in other laminopathies.
- These patients extend the spectrum of abnormal phenotypes caused by LMNA mutations, which may complicate the clinical diagnosis of some patients with laminopathies, but suggest that LMNA is a good candidate for evaluation in patients with other atypical progeroid phenotypes.

**Materials and Methods**

**Study subjects and cell lines**

Thirteen cell lines of patients were obtained from Coriell Cell Repositories (Camden, NJ, USA http://locus.umdnj.edu/CCR/). All coding exons, plus >50 bp of intron-exon selected based on the search terms “atypical progeria” or “progeroid” phenotype: AG00989, AG00990, AG01178, AG03364, AG03829, AG04110, AG05233, AG08467, AG11572, AG12795, AG12799, AG15693, and AG15695. The University of Western Ontario ethics review panel had approved the study.

**Genomic sequencing**

Established methods were used to extract genomic DNA from cell lines. All coding exons, plus >50 bp of intron-exon

**Abbreviations**: AD, autosomal dominant; AR, autosomal recessive; CMD1A, a form of AD-dilated cardiomyopathy; EDMD2, Emery-Dreifuss muscular dystrophy type 2; HGPS, Hutchinson-Gilford Progeria Syndrome; LGMD1B, AD limb girdle muscular dystrophy type 1B; MAD, AR mandibuloacral dysplasia; WRN, Werner’s syndrome
Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes

boundaries and >500 bp of 5' and 3' untranslated flanking regions of the LMNA gene were sequenced on a Prism 377 Automated DNA Sequencer (PE-Applied Biosystems, Mississauga, ON, Canada) using PCR amplification followed by direct genomic sequencing as described previously. Mutations were identified using Sequence Navigator software (PE-Applied Biosystems, Mississauga, ON, Canada). Mutation-containing exons were subsequently screened in samples from 100 clinically normal white subjects, to determine whether any observed genomic variant was also present in the normal population.

Immunofluorescence microscopy
To examine the nuclear morphology of the three mutant cell lines, cultured fibroblasts were plated onto glass coverslips in 6 well plates and grown to approximately 50% confluence. The cells were fixed in −20°C methanol for 20 minutes at room temperature and then made permeable by incubating with 0.1% Triton X-100. Non-specific antibody cross reactivity was blocked by a 30 min pre-incubation in a block solution consisting of phosphate buffered saline with 5% goat serum and 0.3% bovine serum albumin. Cells were then incubated at room temperature for one hour at 37°C with the H-110 primary rabbit polyclonal IgG antibody specific to Lamin A/C (Santa Cruz Biotechnology, Santa Cruz) diluted 1:100 in block solution. Cells were then incubated for one hour at 37°C with a secondary goat anti-rabbit antibody conjugated with green fluorescent dye (Alexa Fluor® 488 goat anti-rabbit IgG, Molecular Probes, USA) at 1:1000 dilution in block solution. The coverslips were then mounted on glass slides in a drop of Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). A fibroblast cell line derived from a normal donor, GM00038C was used as a control for the immunofluorescence studies. Immunofluorescence microscopy was performed on a Perkin Elmer Ultraview LCS scanning disk confocal head with a Nikon 2000E microscope. Images were acquired with a 60 x planapo objective which provided a transverse resolution of 0.17 μm and slice thickness of 0.17 μm. Image stacks through nuclei were obtained and midsection slices were selected to show lamin A/C intensity in laminae cross sections and in the interior of the nucleus. Image staining and acquisition on all samples was done in parallel to minimise artefacts due to variations in staining and illumination. Representative cross section intensity profiles (lines 10 pixels wide) were prepared on confocal slices of nuclear mid sections. Laminae in fibroblasts had equivalent immunostaining intensities.

RESULTS
Mutational screening
Out of 13 cell lines from subjects with ‘atypical progeria’, three had missense mutations in LMNA compared to 0/100 normal control subjects (p = 0.0012, Fisher’s exact test), as shown in fig 1. Subjects AG00989, AG00990, and AG04110 were simple heterozygotes for LMNA missense mutations designated as R644C, T10I, and E578V respectively. All three mutations affected residues in LMNA that are conserved in vertebrates (data not shown). The T10I and R644C mutations are the most 5’ and 3’ missense mutations in LMNA identified to date, with both occurring in the N-terminal head and C-terminal domains of lamin A/C respectively (but with R644C affecting only Lamin A). A diagrammatic representation of the location of the three mutations, along with previously identified mutations causing HGPS, MAD, and atypical WRN can be seen in fig 2.

Genotype phenotype correlations and pleiotropy
The clinical attributes for the three carriers of LMNA mutations identified from the screening experiments are shown in table 1. Each subject had some clinical features that were atypical for classical HGPS. For instance, the original diagnosis for the patient corresponding to cell line AG04110 could not be distinguished between either severe WRN or mild HGPS, and in retrospect the rationale for classifying the patient as WRN was weak. The confounding features included an older age of onset, with some features such as atrophic skin changes, short stature, beak nose and high pitched voice that were common to both HGPS and WRN. The patient corresponding to cell line AG00989 was diagnosed with “atypical progeria” and was noted to have an unspecified type of cachectic dwarfism. However, he had attained an age that was greater than the median age of mortality for HGPS.

The two “atypical progeria” patients with mutant LMNA also expressed components of non-progeroid laminopathies. In particular, the patient corresponding to cell line AG00990, with the T10I mutation, had originally been diagnosed with “atypical progeria”, but was later reclassified as “Seip syndrome” based on generalised lipatrophy and abnormal metabolic biochemical analyses, including elevated triglyceride concentrations and an abnormal glucose tolerance test—reminiscent of features seen in lipodystrophy associated with LMNA. Thus, some of the diseases caused by LMNA mutations may be difficult to classify because of overlapping phenotypic components. The R644C mutation seen in subject AG00989 has previously been reported in a case of CMD1A, and may be an example of a pleiotropic LMNA mutation of variable penetrance causing different disease phenotypes. R644 is part of the putative cleavage recognition sequence (R5Y LLG) for the prelamin A endoprotease, Zmpste24, and the R644C mutation may inhibit the activity of this enzyme. We hypothesise that the pleiotropy of the R644C mutation may be caused by genetic polymorphism in the ability of Zmpste24 to cleave prelamin A. A comprehensive search of the literature revealed that pleiotropy is not unprecedented for LMNA mutations, but has been hitherto unrecognised. For example, the R377H mutation causes both CMD1A and LGMD1B, R133P is causative for both CMD1A and EDMD2, and R133L is causative for both atypical WRN and a complex phenotype encompassing lipodystrophy, cardiomyopathy, liver steatosis and skin lesions. Polymorphisms in prelamin A endoproteases cannot account for these other examples of pleiotropy, for which we postulate the existence of other modifier loci.

Immunofluorescence microscopy
Aberrations of nuclear morphology have been reported in all of the laminopathies, and the three fibroblast cell lines in which we found new LMNA mutations (AG00989, AG00990, AG04110) had a significant proportion of abnormal nuclei characterised by an irregularly shaped nuclear envelope.
There was variation in the severity of nuclear aberration between the three cell lines. Fibroblast line AG00989 had somewhat mildly irregular nuclei (fig 3: A–C), AG00990 had grossly abnormal nuclei (fig 3: D–F) and AG04110 had intermediate nuclear irregularities (fig 3: G–I). We found that not all nuclei were abnormal in the mutant cell lines, and some abnormal nuclei were found in the control cell line, as reported previously. Therefore we scored the percentage of abnormal nuclei (n = 100) in each cell line and obtained the following results: AG00989, 33%; AG00990, 92%; AG04110, 42%; and the control fibroblast GM00038C, 19%. By far the most irregularly shaped nuclei were found in cell line AG00990 (fig 3: D–F), which has the T10I mutation. A high percentage of nuclei in this cell line had multiple, extreme lobulations of the nuclear membrane, resembling somewhat a cauliflower or a bunch of grapes (fig 3: D–F). Some of these lobulations contained no chromatin as revealed by the merging of Toto-3 and Lamin A/C staining (fig 3F), indicating that the lamina had detached from the chromatin. This mutation affects both lamins A and C in the N-terminal head domain, and apparently has dramatic consequences for nuclear morphology, perhaps by disrupting lamin polymerisation, a hypothesis that we are investigating.

**DISCUSSION**

How do different LMNA mutations produce a spectrum of abnormal phenotypes, including HGPS? The LMNA gene products, lamins A and C, are components of the nuclear lamina, which together with nuclear membranes and pore complexes comprise the nuclear envelope. It seems unlikely that the various laminopathies are caused simply by increased nuclear fragility, primarily because the irregularly shaped nuclear envelopes reported here and elsewhere do not correlate to any specific disease phenotype, or even to disease severity. However, mutations in lamins might adversely influence cell division since the lamina becomes depolymerised during mitosis and proper lamin organisation is essential for the transition from initiation to elongation during DNA synthesis in S phase. Secondly, specific nuclear lamin mutations could modify interactions with particular transcription factors, with different effects in different tissues. For example lamin A is already known to interact

---

**Table 1** Clinical and biochemical attributes of atypical progeria subjects with mutant LMNA

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Age, ethnicity, and sex</th>
<th>Diagnosis</th>
<th>Clinical features</th>
<th>LMNA mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AG00990</td>
<td>15 year old white male</td>
<td>Seip syndrome</td>
<td>hypertriglyceridemia, hyperglycaemia, thinned skin, lipoatrophy</td>
<td>T10I heterozygote</td>
</tr>
<tr>
<td>AG04110</td>
<td>13 year old white female</td>
<td>Severe WRN or mild HGPS</td>
<td>progeroid features, short stature, dysmorphic facies, thinned skin, clinodactyly</td>
<td>E578V heterozygote</td>
</tr>
<tr>
<td>AG00989</td>
<td>20 year old white male</td>
<td>&quot;Atypical progeria&quot;</td>
<td>short stature, generalised wasting, thinned skin, survival to relatively older age</td>
<td>R644C heterozygote</td>
</tr>
</tbody>
</table>
with the retinoblastoma (Rb) transcription factor,\textsuperscript{33,34} which is involved in controlling various cellular processes such as cell cycle arrest and apoptosis.\textsuperscript{35} Lamin A mutations could have more general, widespread effects on gene expression since proper lamin organisation is essential for RNA polymerase II dependent transcription.\textsuperscript{36} Thirdly, mutant lamins might disrupt the chromatin organisation that is probably essential for preserving fundamental cellular attributes. We postulate that the wide variation in phenotypes of the laminopathies could be explained by the divergent impacts that different mutations have on the tertiary structure of Lamin A and its subsequent interactions within chromatin domains and with global transcriptional regulators. Consequences might vary between tissues depending on the rescue of these functions by other proteins.

Defining \textit{LMNA} mutation as the causative gene for HGPS, atypical WRN, and now some cases of atypical progeria, not only permits molecular diagnosis and counselling in HGPS families, but also provides a new candidate for evaluation in patients with atypical progeroid syndromes. Dynamic or static nuclear imaging might also be used to permit assignment of numerous idiopathic diseases into the category of laminopathies. While DNA diagnosis of a specific progeroid syndrome may have only limited clinical value at present, future therapies might depend upon having a precise molecular classification.

**ACKNOWLEDGEMENTS**

We thank Dr Robert D Goldman and Dr Dale K Shumaker for maintaining cell lines and providing helpful advice. Ms Christina Williams and Ms Monica Carter provided excellent technical assistance.

**Authors’ affiliations**

A B Csoka, P J Sammak, D Constantinescu, G P Schatten, Pittsburgh Development Center, Magee-Womens Research Institute, Department of Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

H Cao, R A Hegele, Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, London, Ontario, Canada

This work was supported by grants from Canadian Institutes for Health Research (MT13430), the Canadian Genetic Diseases Network and the Blackburn Group to RAH, and NIH support to GPS and the Pittsburgh Development Center.

Dr Hegele holds a Canada Research Chair (Tier I) in Human Genetics and a Career Investigator award from the Heart and Stroke Foundation of Ontario.

![Figure 3](http://jmg.bmj.com/)

**Figure 3** Representative nuclear morphologies of the three mutant fibroblast strains and one control. The left column (panels A, D, G, J) shows nuclear DNA stained with Toto-3 (Molecular Probes, USA), the middle column (panels B, E, H, K) shows cells stained with the Lamin A/C specific polyclonal antibody H-110 (Santa Cruz Biotechnology), and the right column (panels C, F, I, L) is a composite of Toto-3 and Lamin A/C staining. AG00989: A–C, AG00990: D–F, AG04110: G–I, GM00038C: J–L. All panels are shown at the same scale and image intensity, with a scale bar of 20 \(\mu\)m shown at the bottom right of panel L.
Severe bone changes in a case of Hutchinson-Gilford syndrome. Ann Genet


Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes

A B Csoka, H Cao, P J Sammak, D Constantinescu, G P Schatten and R A Hegele

J Med Genet 2004 41: 304-308
doi: 10.1136/jmg.2003.015651

Updated information and services can be found at:
http://jmg.bmj.com/content/41/4/304

These include:

References
This article cites 33 articles, 6 of which you can access for free at:
http://jmg.bmj.com/content/41/4/304#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Metabolic disorders (329)
- Genetic screening / counselling (887)
- Cardiomyopathy (84)
- Dermatology (240)
- Ethics (220)
- Muscle disease (146)
- Neuromuscular disease (257)
- Molecular genetics (1254)
- Calcium and bone (307)
- Ischaemic heart disease (43)
- Osteoporosis (17)
- Peripheral nerve disease (97)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/